AI Bias Analysis
4 models · Takes ~15 seconds
(MedPage Today) -- NEW ORLEANS -- Petrelintide, an investigational long-acting amylin analog, induced significant weight loss with minimal side effects in the global phase II ZUPREME-1 study. By week 28, all five investigational doses of petrelintide...
Source
MedPage Today
Opens original article in a new tab
(MedPage Today) -- NEW ORLEANS -- Participants with obesity achieved weight loss on par with bariatric surgery and had improvements in two obesity-related conditions while taking a once-weekly investigational triple hormone receptor agonist...
You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference.
(MedPage Today) -- NEW ORLEANS -- Monotherapy with once-weekly retatrutide, an investigational triple hormone receptor agonist, improved glycemic control and body weight in adults with type 2 diabetes, the phase III TRANSCEND-T2D-1 trial showed...
(MedPage Today) -- NEW ORLEANS -- Once-daily orforglipron (Foundayo) improved outcomes in adults with type 2 diabetes and inadequate glycemic control, the international ACHIEVE-5 trial showed. In patients already taking background insulin glargine...
